refract: standard chemoimmunotherapy versus novel agents in r/r follicular lymphoma
Published 1 year ago • 197 plays • Length 1:51Download video MP4
Download video MP3
Similar videos
-
2:56
moving towards chemotherapy-free approaches in r/r follicular lymphoma
-
1:36
the changing role of chemotherapy in lymphoma and the value of novel immunotherapies
-
2:36
brentuximab vedotin versus pembrolizumab in r/r classical hodgkin lymphoma
-
2:25
comparative effectiveness of epcoritamab versus real-world usual care in r/r follicular lymphoma
-
1:45
a phase i/ii trial of glofitamab monotherapy in r/r mcl
-
3:26
phase ii study of acalabrutinib, lenalidomide & rituximab for high tumor burden follicular lymphoma
-
7:05
new and emerging therapies for follicular lymphoma, including treatment challenges
-
6:24
tnb-486: interim results of a cd19/cd3 t-cell engager in r/r follicular lymphoma
-
54:31
december 14, 2023 vmr with rabih & cps team - bloody stool and fever
-
1:00
the role of non-covalent btk inhibitors in the treatment of non-hodgkin lymphoma
-
1:09
assessing cardiovascular tolerability of zanubrutinib vs ibrutinib in pts with b-cell malignancies
-
1:29
diagnosis and staging of follicular lymphoma
-
6:16
overview of novel restore and target treatment approach to classical hodgkin lymphoma
-
5:21
chemo-free regimens in lymphoma
-
1:09
novel immunotherapy combinations in hodgkin lymphoma
-
1:06
molecules versus cells for hodgkin lymphoma management
-
1:32
promising novel immunotherapeutic approaches in lymphoma
-
1:27
diagnosis and risk stratification in hodgkin lymphoma: updates and novel approaches
-
1:51
unmet needs in follicular lymphoma
-
1:59
hodgkin lymphoma: prognostic markers in the era of novel treatments
-
10:41
trial updates in follicular lymphoma from ash 2019
-
2:03
advances in pet & radiomics in lymphoma & insights into the international metabolic prognostic index